Clinical Trial Detail

NCT ID NCT03204188
Title Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

CLL/SLL

Therapies

Fludarabine + Ibrutinib + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST